Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

Breast cancer research : BCR

Volumn 7, Issue 4, 2005, Pages

  Esteva, Francisco J ^a   Cheli, Carol D ^a   Fritsche, Herbert ^a   Fornier, Monica ^a   Slamon, Dennis ^a   Thiel, Robert P ^a   Luftner, Diana ^a   Ghani, Farooq ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; DISEASE COURSE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 33644528230     PISSN: None     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1020     Document Type: Article

References (0)